AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01115582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholic acid
Description: The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.~Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child.
Study NCT01053585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
Study NCT01053585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single 'dose' 90 minutes prior to study
Study NCT01108445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
Study NCT01108445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
Study NCT01824940 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard Care:~* Exclusive breastfeeding promotion for all infants, birth to 6 months~* Strengthened PMTCT (prevention of mother to child transmission of HIV) services~* Strengthened Village Health Worker system
Study NCT01824940 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WASH
Description: WASH:~* Standard care interventions~* Provide household ventilated pit latrine, water treatment solution, and monthly liquid soap, two hand-washing facilities and protected infant play space~* Provide interpersonal communication interventions promoting feces disposal in a latrine, HWWS (hand washing with soap), drinking water treatment, hygienic weaning food preparation, and preventing babies from putting dirt and animal feces in their mouths.
Study NCT00810927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suction cup application
Description: he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
Study NCT00810927 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Suction cup application
Description: he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
Study NCT01824940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Infant and young child feeding
Description: IYCF:~* Standard care interventions~* Provide 20 g/d Nutributter from 6-18 months~* Provide interpersonal communication interventions promoting optimal use of locally available foods for complementary feeding after 6 months, continued breastfeeding and feeding during illness.
Study NCT01824940 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WASH and Nutrition
Description: WASH AND IYCF interventions~* Standard care interventions~* All WASH interventions~* All IYCF interventions
Study NCT01120444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD Research Catheter with 34G x 1.5 mm needle
Description: bolus injection of insulin given intradermal prior to standardized meal
Study NCT01120444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set
Description: bolus delivery of insulin given subcutaneously prior to standardized meal
Study NCT02032212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVP unflavoured
Study NCT02032212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVP flavoured
Study NCT03783663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Misfit Shine 2
Description: The intervention group was given a Misfit Shine 2 to monitor sleep throughout the 12-week intervention period. Participants were instructed to wear the device on the wrist, which is better for capturing sleep than the other wear locations. Participants were instructed on how to self-monitor total sleep time and select a goal for that behavior. Further, participants were asked to view feedback on their sleep time daily on the Misfit smartphone app, which they used to monitor their progress toward achieving their behavioral goals.
Study NCT03393351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision-making program
Description: The intervention is shared decision-making. The implementation strategy to foster shared decision-making in routine cancer care is a multicomponent implementation program. The implementation program consists of the following components:~1. shared decision-making trainings for health care professionals,~2. individual coaching for physicians,~3. patient activation strategy,~4. provision of patient information material and decision aids,~5. revision of the clinics quality management documents, and~6. critical reflection of current organization of multidisciplinary team meetings.~Implementation: after baseline assessment (t0) for clinic 1, after assessment at t1 for clinic 2, after assessment at t2 for clinic 3.
Study NCT03393351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: No specific study related intervention. Treatment decisions are made according to current routine practice at the comprehensive cancer center in Germany.
Study NCT04165395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Five-layer foam dressing
Description: Five-layer foam dressing applied on the sacrum within 48 hours of spinal surgery
Study NCT04165395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heelmedix boot
Description: Heelmedix boot will be installed alternately from one foot to the other.
Study NCT01360333 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: tap water, sodium chloride, carbohydrate rich fluid
Description: Ingestion of three different fluids at three different occasions separated by at least one week, A, Tap water. B. Sodium Chloride. C. Carbohydrate rich fluid.
Study NCT03641001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child feeding counselling, food voucher, micronutrient powder, WASH
Description: Child feeding counselling will be assisted by food voucher, micronutrient powder and WASH messages
Study NCT01712906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.50±0.25logCCID50/ml
Description: Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
Study NCT02032212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine inhalator
Description: 15 mg nicotine Nicorette
Study NCT01712906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4.25±0.25 logCCID50/ml
Description: Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
Study NCT01712906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5.00±0.25 logCCID50/ml
Description: Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
Study NCT01712906 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0 logCCID50/ml
Description: 0 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
Study NCT01712906 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1)
Description: Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in children (2-4 years old) and infants (8-23 months old) on day 0.
Study NCT02722187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subinguinal microscopic varicocelectomy
Study NCT02032212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional cigarette
Study NCT01304719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Assisted Healthy Families America Home Visitation
Description: Computer modules added to home visitation protocol for Healthy Families America
Study NCT01304719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Families America Home Visitation
Description: Healthy Families America Home Visitation Treatment as Usual
Study NCT00884598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Study NCT00884598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT00884598 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00265642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: one tablet of 150 mg/d during 2 years
Study NCT00265642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet per day during 2 years
Study NCT01426659 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: parental stimulation according to protocol
Description: verbal stimulation every day image of the Protocol Dire et Faire
Study NCT03050489 — intervention group
Intervention type: PROCEDURE
Intervention: On-Pump CABG.
Description: Standard On-Pump CABG.
Study NCT03050489 — intervention group
Intervention type: PROCEDURE
Intervention: Off-Pump CABG.
Description: Standard Off-Pump CABG.
Study NCT03050489 — intervention group
Intervention type: PROCEDURE
Intervention: BH-CABG MSC.
Description: Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation
Study NCT01031615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child and Family Traumatic Stress Interv (CFTSI)
Description: 4 sessions involving both the target child and a parent/caregiver
Study NCT01031615 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Comparison
Description: 4 individually focused sessions including psychoeducation and relaxation.
Study NCT04285684 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ketamine in lactation
Description: 2 dose IM by weight and assessing concentrations of ketamine in expressed milk at intervals
Study NCT02269449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6Fr Glidesheath Slender sheath
Description: 6Fr sheath (Glidesheath slender: GSS), which is characterized with the same inner lumen diameter with contemporary 6Fr sheath as well as the sheath outer diameter similar with contemporary 5Fr sheath.
Study NCT02269449 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5Fr sheath
Description: 5Fr Hydrophilic coating sheath from Terumo.
Study NCT02269449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemostasis with TR band
Description: Hemostasis is achieved using TR band (TERUMO) Patent hemostasis.
Study NCT02269449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Any hemostasis procedure
Description: Hemostasis is achieved by any hemostasis of each hospital's routine procedure.
Study NCT00574951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motesanib diphosphate
Study NCT01791400 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: metoclopramide, injection,20mg, one time
Description: metoclopramide, intravenous injection,20mg, one time
Study NCT00810927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Doppler flowmetry
Description: Measurement of choroidal blood flow
Study NCT00810927 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laser Doppler flowmetry
Description: Measurement of choroidal blood flow
Study NCT00810927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of intraocular pressure
Study NCT00810927 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Measurement of intraocular pressure
Study NCT03324581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-64005
Description: OPC-64005 film coated tablets
Study NCT03324581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Atomoxetine gelatin capsules
Study NCT03324581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules
Study NCT03324581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules
Study NCT03324581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules
Study NCT01791400 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sumatriptan, injection, 6 mg, one time
Description: Sumatriptan, subcutaneous injection, 6 mg, one time
Study NCT01203176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic polypectomy
Description: Hysteroscopy is a well established minimally invasive surgery method for diagnostic and intervention operations inside the uterine cavity. Using this method one can observe the endometrium and remove polyps.
Study NCT01203176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopic polypectomy
Description: Hysteroscopy is a well established minimally invasive surgery method for diagnostic and intervention operations inside the uterine cavity. Using this method one can observe the endometrium and remove polyps.
Study NCT03696927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Powered Prosthesis (APEX) for Spinal Cord Injury
Description: The Active Powered Prosthesis (APEX) is a proof-of-concept shoulder-elbow-wrist device intended to provide non-invasive active powered robotic assistive movement to upper extremities. Focus group participants will control the APEX device on a test manikin and provide feedback on the device design and function.
Study NCT03518671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy, face to face
Description: self-limited cognitive behavioral therapy delivered weekly for 6 weeks via face-face delivery method
Study NCT03518671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy, telemedicine
Description: self-limited cognitive behavioral therapy delivered weekly for 6 weeks via tablet-based telemedicine platform
Study NCT01165736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05186462
Description: single intravenous infusion of 100 microgram
Study NCT03914014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue manipulation
Description: From the estimated date of ovulation to the onset of menstrual bleeding, connective tissue massage will be applied to the sacral, lumbar, lower thoracic and anterior pelvic regions for 5 days per week. The application will take 10 min. During the massage treatment, the physiotherapist will touch the end of the middle finger with the skin of the patient and apply the skin to the pull. The patient will be in the supine position during the treatment of the anterior pelvic region while the patient is in the sitting position during the treatment of the back area.
Study NCT03914014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo ultrasound
Description: From the estimated date of ovulation to the beginning of the next menstrual bleeding, placebo ultrasound will be applied a total of 10 minutes (5 minutes for sacral and lumbar, and lower thoracic regions and 5 min for the anterior pelvic region). Placebo ultrasound application will be performed with superficial circular movements without applying excessive pressure. During the application, the device will only be switched on, the dose will not be adjusted and the patient will be given an image of ultrasound dose.
Study NCT03588000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthen self-monitoring of blood glucose
Description: Strengthen self-monitoring of blood glucose by Internet mobile terminal（APP）.
Study NCT03479346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GGT
Description: Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study NCT03479346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study NCT01215240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis
Description: Prophylactic peritoneal dialysis
Study NCT03912805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin, Type A
Description: topical liniment
Study NCT03912805 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation
Study NCT01093885 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ambrisentan
Description: Drug is dispensed in tablet form. Ambrisentan with anti-fibrotic to assess benefit on skin~Dosing of ambrisentan will begin at 5mg daily for the first month. Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week.
Study NCT00598481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan is used for non-myeloablative conditioning
Study NCT02778282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MySafeRx™
Description: The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
Study NCT04008030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT04008030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Specified dose on specified days
Study NCT04008030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Specified dose on specified days
Study NCT00657501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone gel
Description: once daily transdermal gel, 300 mcg
Study NCT00657501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: once daily transdermal placebo gel
Study NCT04008030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Specified dose on specified days
Study NCT04008030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Specified dose on specified days
Study NCT04008030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Specified dose on specified days
Study NCT04008030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Specified dose on specified days
Study NCT04008030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03416504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gradual Exposure (EXP-G)
Description: In EXP-G, exposure proceeded hierarchically from mildly, to moderately, to highly intense stimuli so that exposure intensity gradually built between (but not within) sessions.
Study NCT03416504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variable Exposure (EXP-V)
Description: In EXP-V, exposure stimuli were chosen at random (i.e., pieces of paper with exposure stimuli written on them were pulled randomly from an opaque container) so that mild, moderate, and high intensity exposures could occur in any order during any of the sessions (the participant was not informed which level was coming next). This aimed to maximize (a) uncertainty, (b) variability in exposure intensity, and (c) variability in corresponding physiological arousal.
Study NCT03395938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Proactive engagement
Description: The engagements would include (1) a sealed envelope containing a cancer information sheet and an invitation letter directed towards siblings for them to contact the research team, (2) weekly phone reminders to the participants for a total of 4 weeks in a bid to remind participants of the need to convey the screening message to their siblings. The envelope will contain information on the various means for the siblings to contact the research team. These include communication means such as electronic mails (emails), telephone, hard copy returned mails through pre-paid envelopes, short messaging services (SMSs) or clinic consult.